Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Labs Will Help Artus Market, Distribute PCR-based SARS Test

NEW YORK, May 15 - Abbott Laboratories has penned a worldwide marketing and distribution agreement with German-based Artus for what is believed to be the first commercial PCR-based test to detect a form of the coronavirus linked to SARS.


Terms of the agreement call for Artus to manufacture the test, and for Abbott to  market and distribute it initially for use on the Roche LightCycler thermal cycler system in North America, the UK, Germany, and Austria. In addition, within several weeks the test will be available worldwide on the Applied Biosystems ABI Prism 7000 Sequence Detection System.

 

Abbott will also help Artus submit the test to the US Food and Drug Administration "as quickly as possible," and will market and distribute it through its molecular diagnostics alliance with Celera Diagnostics. That alliance, struck in June 2002, was designed to develop and market "a broad menu" of molecular diagnostics for various "unmet" undisclosed diagnostic needs.

The test, developed by Artus with the Bernhard-Nocht-Institute for Tropical Medicine  in Hamburg, Germany, has already been introduced by Artus in April to countries in Europe and Asia. The Abbott agreement will "supplement" this distribution network, Artus said. The test has also been provided to laboratories overseen by the World Health Organization and "other major clinical sites" conducting research on the virus.

 

"We believe this new test is sensitive enough to detect the virus in the early stages of infection," said James Koziarz, vice president, diagnostic products research and development, Abbott Labs.

 



GenomeWeb Coverage of SARS

 

German Group Explores SARS Coronavirus Proteinase Structure (May 13, 2003)

///issues/news//121942-1.html"ONT-SIZE: 12pt; FILTER: ; MARGIN: 0in 0in 0pt; BOTTOM: 0px; FONT-FAMILY: 'Times New Roman'">Study Analyzes How SARS Virus Changed As It Spread Across the Globe (May 9, 2003)

///issues/news//121942-1.html"/font>

CombiMatrix Develops siRNA to Target SARS Virus (May 7, 2003)

Affymetrix to Offer SARS GeneChip (May 6, 2003)

///issues/news//121942-1.html" (May 2, 2003)

Roche to Launch RT-PCR-based SARS Diagnostic by July (April 28, 2003)

///issues/news//121942-1.html"

CombiMatrix's Ali Arjomand on Developing a SARS Microarray ( ///issues/news//121942-1.html"tyle="FONT-SIZE: 10pt; COLOR: #040000">University of Manitoba Proteomics Researchers Tackle SARS Virus Proteins ( ///issues/news//121942-1.html">   (April 21, 2003)

Singapore Team Finishes SARS Virus Genome; Canadian Scientists Identify Viral Proteins  (April 17, 2003)

///issues/news//121942-1.html"">CombiMatrix Creates Microarray Based on SARS Genome Data   (April 16, 2003)
///issues/news//121942-1.html"/font>

CDC Completes SARS Virus Genome Draft On Heels of Canadian Team  (April 14, 2003)

///issues/news//121942-1.html"

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more